Last reviewed · How we verify
Induction of remission in adults with moderately to severely active ulcerative colitis
Approved treatments
- Etrasimod · Pfizer
Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes. - Velsipity · Pfizer Inc.
Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs.
Clinical guidelines
- FDA label — any
VELSIPITY is indicated for the induction of remission in adults with moderately to severely active ulcerative colitis. - FDA label — any
VELSIPITY is indicated for the induction of remission in adults with moderately to severely active ulcerative colitis.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Induction of remission in adults with moderately to severely active ulcerative colitis patent landscape — cliff calendar, originator estates, attackable patents
- Induction of remission in adults with moderately to severely active ulcerative colitis treatment landscape brief
- Induction of remission in adults with moderately to severely active ulcerative colitis treatment updates RSS
Frequently asked questions about Induction of remission in adults with moderately to severely active ulcerative colitis
What drugs treat Induction of remission in adults with moderately to severely active ulcerative colitis?
Tracked treatments include Etrasimod, Velsipity.
What is the treatment for Induction of remission in adults with moderately to severely active ulcerative colitis?
Standard treatment for Induction of remission in adults with moderately to severely active ulcerative colitis includes Etrasimod, Velsipity. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Induction of remission in adults with moderately to severely active ulcerative colitis?
FDA label publishes guidelines for Induction of remission in adults with moderately to severely active ulcerative colitis. 2 guideline references tracked.
Related
- Treatment landscape: Induction of remission in adults with moderately to severely active ulcerative colitis patent cliff · Induction of remission in adults with moderately to severely active ulcerative colitis CI report
- Treatment: Etrasimod · Pfizer
- Treatment: Velsipity · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing